CareDx reported strong Q3 2026 financial results, significantly exceeding revenue consensus and posting a positive adjusted EPS. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, driven by a substantial increase in testing volume, indicating robust operational performance and positive future outlook.
CareDx announced Q3 2026 revenue of $139.4 million, significantly beating the FactSet consensus of $122.0 million, and reported an adjusted EPS of $0.70. This strong performance, highlighted by a 51% year-over-year increase in testing volume and a healthy adjusted EBITDA margin of 22%, led the company to raise its full-year 2026 revenue guidance to $520-$530 million and adjusted EBITDA to $90-$100 million. This is a major positive catalyst for CareDx (CDNA), indicating strong underlying business momentum and improved profitability. Short-term, this news is likely to drive CDNA stock higher as investors react to the beat and raise. Long-term, it suggests sustained growth in its testing services, positioning the company favorably in the diagnostics market. The key opportunity for traders is a potential upside move in CDNA shares due to the significantly improved outlook.